Tsugawa K, Hashizume M, Migou S, Kishihara F, Kawanaka H, Tomikawa M, Sugimachi K
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Digestion. 2000;61(2):98-106. doi: 10.1159/000007741.
Portal hypertensive gastropathy (PHG) is now recognized as a distinct entity; however, the angiogenesis in the portal hypertensive gastric mucosa has yet to be elucidated. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor involved in both physiological and pathological angiogenesis. The aim of this study was thus to examine the function of VEGF in the portal hypertensive and non-portal hypertensive gastric mucosa.
Forty-five cirrhotic patients were divided into 3 groups as follows. Group I included 15 patients without PHG who were treated with 1.5 g teprenone/day for 8 weeks: PHG(-)-t. Group II included 15 patients with PHG who were not treated with teprenone: PHG(+)-n. Group III included 15 patients with PHG who were treated with teprenone for 8 weeks: PGH(+)-t. The gastric mucosal blood flow (GMBF), the concentration of gastric mucosal VEGF and hexosamine and the endoscopic findings were studied both before and after medication.
Before teprenone treatment, the GMBF in the antrum, fundus, fornix were significantly higher in PHG(+)-n than PHG(-)-t. After treatment, the GMBF in the fundus and fornix significantly decreased more than before treatment in the PHG(+)-t. After treatment, the GMBF in the antrum increased significantly more than before treatment in PHG(-)-t. The gastric VEGF and hexoxamine concentration in the antrum were significantly higher in PHG(+)-n than in PHG(-)-t. After treatment, the gastric VEGF and hexosamine concentration in the antrum significantly decreased in PHG(+)-t while no change in concentration was recognized in PHG(+)-n. In the endoscopic findings, a decrease in the PHG score was recognized in 2 patients in PHG(+)-t.
Portal hypertensive gastric mucosal change was thus found to trigger a high concentration of VEGF and hexosamine. Such increased activity of VEGF and hexosamine may thus account for the presence of active congestion in PHG.
门脉高压性胃病(PHG)现已被确认为一种独特的疾病;然而,门脉高压性胃黏膜中的血管生成情况尚未阐明。血管内皮生长因子(VEGF)是一种强效血管生成因子,参与生理和病理血管生成过程。因此,本研究旨在探讨VEGF在门脉高压性和非门脉高压性胃黏膜中的作用。
45例肝硬化患者分为以下3组。第一组包括15例无PHG的患者,每天服用1.5 g替普瑞酮,持续8周:PHG(-)-t组。第二组包括15例有PHG但未接受替普瑞酮治疗的患者:PHG(+)-n组。第三组包括15例有PHG且接受替普瑞酮治疗8周的患者:PGH(+)-t组。在用药前后对胃黏膜血流量(GMBF)、胃黏膜VEGF和己糖胺浓度以及内镜检查结果进行研究。
在替普瑞酮治疗前,PHG(+)-n组胃窦、胃底、穹窿部的GMBF显著高于PHG(-)-t组。治疗后,PHG(+)-t组胃底和穹窿部的GMBF较治疗前显著降低。治疗后,PHG(-)-t组胃窦的GMBF较治疗前显著增加。PHG(+)-n组胃窦部的胃VEGF和己糖胺浓度显著高于PHG(-)-t组。治疗后,PHG(+)-t组胃窦部的胃VEGF和己糖胺浓度显著降低,而PHG(+)-n组浓度无变化。在内镜检查结果方面,PHG(+)-t组有2例患者的PHG评分降低。
因此发现门脉高压性胃黏膜改变会引发VEGF和己糖胺的高浓度。VEGF和己糖胺的这种活性增加可能是PHG中存在活动性充血的原因。